Ozempic vs Zepbound: The Honest Comparison
These two drugs get compared constantly, but they aren't built for the same job. Ozempic (semaglutide) is a type 2 diabetes drug used off-label for weight loss; Zepbound (tirzepatide) is FDA-approved for weight loss and hits 22.5% peak weight loss in SURMOUNT-1 versus Ozempic's 11.6% in a diabetes trial. Below: the cost-per-pound math, monthly pricing by channel, and the one distinction (do you have diabetes?) that decides which comparison you should actually be running.
Read this first: they play different positions
- If you have type 2 diabetes: Ozempic is on-label and usually covered. The stronger tirzepatide option for you is Mounjaro (the diabetes-labeled twin of Zepbound), so your real decision is Ozempic vs Mounjaro.
- If your goal is weight loss and you don't have diabetes: the on-label semaglutide is Wegovy, not Ozempic, so the fair fight is Wegovy vs Zepbound. Ozempic just happens to be the name people know.
Weight loss comparison (220 lbs starting weight)
% of body weight lost over 18 months, modeled from phase 3 trial data
The cost-per-pound-lost math (cash-pay, 220 lb starting weight)
For a cash-pay patient chasing weight loss, this is the number that matters: total dollars spent to reach each drug's trial-reported peak, divided by pounds lost. Zepbound wins on both axes - lower branded cash floor and far more weight loss.
| Drug | Cash floor/mo | Months to peak | Total spend | Lbs lost | Cost per lb |
|---|---|---|---|---|---|
| Ozempic | $399 | 15.7 mo | $6,244 | 25.5 lbs | $245/lb |
| Zepbound | $299 | 16.6 mo | $4,955 | 49.5 lbs | $100/lb |
Cash floor = the cheapest branded route for each drug. Ozempic has no manufacturer self-pay program, so its floor is branded telehealth (~$399/mo); Zepbound's floor is LillyDirect self-pay vials (~$299/mo, starter dose). Assumes the floor price held flat through the trial-reported time-to-peak; actual totals vary with dose-specific tiers and titration pace. Ozempic's 11.6% is from a type-2-diabetes trial (STEP-2 (T2D)). See sources for trial citations.
Monthly cost by payment channel
| Channel | Ozempic | Zepbound |
|---|---|---|
| Insurance copay (typical) | $63 | $88 |
| Manufacturer self-pay | - | $299 |
| Branded telehealth | $399 | $499 |
| Cash retail (full WAC) | $1,028 | $1,059 |
Two honesty notes on the insurance row: Ozempic's copay assumes you have type 2 diabetes(it is not covered for weight loss alone), and Zepbound's assumes a plan that actually covers weight-loss drugs with a prior authorization - many plans cover neither. Ozempic shows a dash for manufacturer self-pay because no such program exists for it. Pricing as of July 2026.
Ozempic pros and cons
- ✓ Often easier to get insurance coverage if you have type 2 diabetes
- ✓ Lower list price than Wegovy
- ✓ Same active ingredient as Wegovy (semaglutide)
- ✓ Strong cardiovascular outcome data (SUSTAIN-6)
- ✗ Off-label for weight loss - insurance won't cover for that purpose
- ✗ Lower max dose than Wegovy (2.0 mg vs 2.4 mg) means slightly less weight loss
- ✗ Periodic shortages
Zepbound pros and cons
- ✓ Highest efficacy of any FDA-approved GLP-1 (22.5% in SURMOUNT-1)
- ✓ Dual GLP-1/GIP mechanism
- ✓ LillyDirect self-pay vials starting around $349/mo for lower doses
- ✓ FDA-approved for chronic weight management
- ✗ List price still high ($1,059/mo)
- ✗ Insurance coverage varies more than for Wegovy
- ✗ GI side effects can be more pronounced at higher doses
- ✗ Periodic supply constraints during demand spikes
Which one fits your situation?
Zepbound if:weight loss is the goal, you're paying cash or have a plan that covers weight-loss drugs, and you want the most weight loss per dollar - the cost-per-pound math above favors it decisively over branded Ozempic.
Ozempic if:you have type 2 diabetes (so it's on-label and covered), your prescriber is treating blood sugar first with weight loss as a welcome side effect, or Zepbound simply isn't covered by your plan and cash Zepbound doesn't fit the budget.
Neither - look one drug over:if you don't have diabetes and want semaglutide specifically, ask about Wegovy (the weight-loss-approved, higher-dose, self-pay-supported version of Ozempic's molecule). If you have diabetes and want tirzepatide's strength, ask about Mounjaro (Zepbound's diabetes-labeled twin).
Educational content only, not a treatment recommendation. Any switch or new prescription should go through a licensed prescriber.
Where to actually get Ozempic, Zepbound, or the alternatives
Manufacturer direct prices (LillyDirect, NovoCare) are usually cheapest. Updated May 2026.
| Drug | Insurance | Mfr direct | Telehealth (brand) | Telehealth (compd) | Cash retail | Get it |
|---|---|---|---|---|---|---|
| Wegovy 14.9% weight loss | $63 | $349 | $329 | $249 cheapest | $1,349 | Get →ad |
| Ozempic 11.6% weight loss | $63 | - | $399 | $199 cheapest | $1,028 | Get →ad |
| Wegovy (oral 25mg) 13.6% weight loss | $63 | $149 cheapest | $449 | - | $1,349 | Get →ad |
| Zepbound 22.5% weight loss | $88 | $299 cheapest | $499 | $299 cheapest | $1,059 | Get →ad |
| Mounjaro 20.9% weight loss | $88 | - | $499 | $299 cheapest | $1,069 | Get →ad |
| Saxenda 8.4% weight loss | $63 | - | $399 cheapest | - | $1,349 | Get →ad |
| Foundayo (orforglipron) 14.7% weight loss | $63 | $149 cheapest | - | - | $1,099 | Get →ad |
Frequently asked questions
Is comparing Ozempic and Zepbound even a fair fight?
Not quite, and it's worth being honest about why. Ozempic (semaglutide) is FDA-approved for type 2 diabetes, not weight loss - people use it off-label to lose weight, but its on-label job is blood-sugar control, and its top dose (2.0 mg) is lower than the weight-loss version of the same molecule (Wegovy, 2.4 mg). Zepbound (tirzepatide) is FDA-approved specifically for chronic weight management and reaches 22.5% peak weight loss in SURMOUNT-1. If your goal is purely weight loss and you're paying cash, the apples-to-apples comparison is really Wegovy vs Zepbound, both weight-loss-approved. Ozempic vs Zepbound only becomes the right question when you have type 2 diabetes, because then Ozempic's on-label status changes what insurance will pay for.
Which one causes more weight loss?
Zepbound, clearly, on the trial numbers: 22.5% peak weight loss in SURMOUNT-1 versus 11.6% for Ozempic in STEP-2. Two caveats matter. First, Ozempic's 11.6% comes from a type-2-diabetes trial, and diabetics typically lose somewhat less weight on any GLP-1 than people without diabetes - a non-diabetic on Ozempic off-label may land a little higher, though still below Wegovy because of the lower 2.0 mg ceiling. Second, tirzepatide (Zepbound) hits two gut-hormone receptors (GLP-1 and GIP) while semaglutide (Ozempic) hits one, which is the mechanistic reason for the efficacy gap. Bottom line: for weight loss specifically, Zepbound out-performs Ozempic in every published dataset.
Which is cheaper?
It depends entirely on whether you have type 2 diabetes. Paying cash for weight loss, Zepbound is actually cheaper AND more effective: LillyDirect self-pay vials start around $299/mo, while Ozempic has no manufacturer self-pay program at all - Novo Nordisk routes cash-pay weight-loss patients to Wegovy's NovoCare, so branded Ozempic without insurance means telehealth at roughly $399/mo. But if you have type 2 diabetes, the math flips: Ozempic is on-label and widely covered, so your copay might be $63/mo, while Zepbound (weight-loss-approved, not diabetes-approved) may not be covered for you at all without a separate obesity diagnosis and prior authorization.
I have type 2 diabetes - should I pick Ozempic or Zepbound?
For type 2 diabetes, the cleaner comparison is actually Ozempic vs Mounjaro, because Mounjaro is the diabetes-approved version of the exact same molecule as Zepbound (tirzepatide). Zepbound and Mounjaro are both tirzepatide; Zepbound just carries the weight-loss label and Mounjaro carries the diabetes label. If you have T2D and your doctor wants tirzepatide's stronger effect, they'll typically prescribe Mounjaro (on-label, covered) rather than Zepbound (off-label for diabetes). So the real diabetes decision is Ozempic vs Mounjaro - see that guide for the coverage and A1C details.
What is the dosing and injection difference?
Both are once-weekly subcutaneous injections. Ozempic escalates 0.25 → 0.5 → 1.0 → 2.0 mg and comes as a multi-dose prefilled pen. Zepbound escalates 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg over 20+ weeks, and its format depends on how you buy it: pharmacy-dispensed Zepbound (insurance or full retail) is a single-dose auto-injector pen, while LillyDirect self-pay Zepbound ships as single-dose vials you draw with a syringe - Lilly's tradeoff for the lower cash price. If manual vial-and-syringe dosing is a dealbreaker, factor that into the Zepbound self-pay route specifically.
Are the side effects different?
Both share the same core GI side-effect profile - nausea, diarrhea, constipation, vomiting - because both slow gastric emptying and blunt appetite through GLP-1 receptor activation. Zepbound adds GIP-receptor activity and titrates to a higher relative potency, which can mean more pronounced GI effects during dose escalation for some people, though this varies a lot individually. There's no clean "one is gentler" answer in head-to-head data. If you've already tolerated semaglutide (Ozempic) reasonably well, that's useful information for your prescriber, but it doesn't guarantee the same experience on tirzepatide.
Can I use my Ozempic savings card on Zepbound?
No. Manufacturer savings cards are drug-specific and manufacturer-specific - the Ozempic Savings Card is a Novo Nordisk program, the Zepbound Savings Card is an Eli Lilly program, and neither transfers. Both also require existing commercial insurance coverage of that specific drug to work, and both exclude government insurance (Medicare, Medicaid, TRICARE, VA) by federal anti-kickback rules. If you switch drugs, you apply for the new manufacturer's card from scratch.
Should I be asking about Wegovy instead of Ozempic?
Very possibly, if weight loss is the goal and you don't have diabetes. Wegovy is the same molecule as Ozempic (semaglutide) but FDA-approved for weight loss, dosed higher (2.4 mg vs 2.0 mg), and backed by a manufacturer self-pay program (NovoCare) that Ozempic lacks. So for a cash-pay weight-loss patient, the honest bracket is Wegovy vs Zepbound - not Ozempic vs Zepbound. The Wegovy vs Zepbound guide runs that cost-per-pound comparison directly.
Related guides
Stay ahead of every GLP-1 development
We'll email you when something actually matters: new FDA approvals (Foundayo, CagriSema, retatrutide), pricing drops at LillyDirect/NovoCare, telehealth deals, clinical trial results, FDA recalls, and insurance policy changes. ~1-2 emails/month. No filler.